Last: | $1.56 |
---|---|
Change Percent: | 1.3% |
Open: | $1.52 |
Close: | $1.56 |
High: | $1.6 |
Low: | $1.52 |
Volume: | 39,155 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.56 | $1.52 | $1.56 | $1.6 | $1.52 | 39,155 | 05-01-2024 |
$1.54 | $1.51 | $1.54 | $1.54 | $1.51 | 27,357 | 04-30-2024 |
$1.51 | $1.52 | $1.51 | $1.52 | $1.5 | 43,612 | 04-29-2024 |
$1.5 | $1.47 | $1.5 | $1.52 | $1.47 | 38,503 | 04-26-2024 |
$1.48 | $1.47 | $1.48 | $1.49 | $1.46 | 17,141 | 04-25-2024 |
$1.47 | $1.5 | $1.47 | $1.51 | $1.46 | 81,743 | 04-24-2024 |
$1.49 | $1.5 | $1.49 | $1.5 | $1.47 | 33,829 | 04-23-2024 |
$1.48 | $1.52 | $1.48 | $1.52 | $1.47 | 71,949 | 04-22-2024 |
$1.5 | $1.51 | $1.5 | $1.52 | $1.5 | 45,504 | 04-19-2024 |
$1.51 | $1.51 | $1.51 | $1.54 | $1.5 | 27,601 | 04-18-2024 |
$1.505 | $1.52 | $1.505 | $1.52 | $1.5 | 28,482 | 04-17-2024 |
$1.52 | $1.5 | $1.52 | $1.52 | $1.5 | 61,777 | 04-16-2024 |
$1.5 | $1.55 | $1.5 | $1.55 | $1.5 | 35,729 | 04-15-2024 |
$1.52 | $1.51 | $1.52 | $1.526 | $1.5 | 97,303 | 04-12-2024 |
$1.5 | $1.5 | $1.5 | $1.52 | $1.5 | 26,223 | 04-11-2024 |
$1.51 | $1.55 | $1.51 | $1.6 | $1.5 | 147,605 | 04-10-2024 |
$1.55 | $1.58 | $1.55 | $1.593 | $1.51 | 59,722 | 04-09-2024 |
$1.56 | $1.65 | $1.56 | $1.65 | $1.55 | 47,866 | 04-08-2024 |
$1.57 | $1.6 | $1.57 | $1.6 | $1.52 | 117,092 | 04-05-2024 |
$1.57 | $1.56 | $1.57 | $1.64 | $1.56 | 37,017 | 04-04-2024 |
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company develo...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been e...